89O BMS-986504 with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
In the phase 1 CA240-0007 study, BMS-986504 (MTA-cooperative PRMT5 inhibitor) was well tolerated and had antitumor activity in pts with MTAP-del advanced solid tumors, including PDAC. Here, we report updated clinical outcomes with BMS-986504 monotherapy and initial efficacy and safety data for BMS-986504 + GEM + nab-P in substudy 3 (SS3) of pts with PDAC.
Fields of Study & Subjects
Pancreatic and Hepatic Oncology Research
Peptidase Inhibition and Analysis
PARP inhibition in cancer therapy
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106231–106231
- Publication date
- 1 April 2026
- Language
- EN